益盛药业(002566) - 2023 Q2 - 季度财报

Financial Performance - The company's operating revenue for the first half of 2023 was ¥469,428,507.08, representing a 9.57% increase compared to ¥428,409,146.26 in the same period last year[24]. - The net profit attributable to shareholders of the listed company was ¥47,428,322.86, an increase of 8.25% from ¥43,812,015.69 year-on-year[24]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥36,945,048.36, up 12.58% from ¥32,817,432.17 in the previous year[24]. - The net cash flow from operating activities increased by 60.55% to ¥116,279,461.95, compared to ¥72,426,598.89 in the same period last year[24]. - The total assets at the end of the reporting period were ¥3,012,806,349.84, a 1.56% increase from ¥2,966,606,675.95 at the end of the previous year[24]. - The net assets attributable to shareholders of the listed company were ¥2,185,858,928.66, reflecting a 1.43% increase from ¥2,154,978,185.80 at the end of the previous year[24]. - The basic earnings per share for the reporting period was ¥0.1433, an increase of 8.23% from ¥0.1324 in the same period last year[24]. - The company's cash flow from operating activities increased significantly by 60.55%, amounting to ¥116,279,461.95, compared to ¥72,426,598.89 in the previous year[47]. - The company reported a net increase in cash and cash equivalents of 57.99%, totaling ¥83,657,004.16, compared to ¥52,950,604.57 in the previous year[47]. - The total comprehensive income for the first half of 2023 was CNY 45,953,590.56, down from CNY 81,907,555.86 in the first half of 2022, indicating a decline of 43.8%[138]. Market and Product Development - The company has developed 11 dosage forms and 117 varieties, with 49 products included in the National Basic Medical Insurance Drug List[36]. - The company has established a complete ginseng industry chain, expanding from pharmaceuticals to cosmetics and health foods[36]. - Yisheng Ginseng Cosmetics has developed over 500 products, including facial cleansers, whitening, anti-wrinkle, acne treatment, and body care products, expanding its ginseng industry chain[38]. - The company has obtained 8 invention patents for ginseng-based cosmetics, filling a market gap in China[38]. - The company plans to continue expanding its market presence and investing in new product development to drive future growth[134]. - The company aims to leverage technological innovation and market expansion to ensure sustainable development amid a challenging economic environment[32]. Research and Development - The company has received 14 patents and 2 scientific achievements related to ginseng cultivation technology[37]. - The Zhenyuan Capsule, a national medical insurance category B product, has been involved in 147 published papers, with 11 indexed by SCI, demonstrating its efficacy in treating coronary heart disease and related conditions[38]. - The Xinyue Capsule has published 238 academic papers, with 23 indexed by SCI, focusing on coronary heart disease and angina treatment[39]. - The Shengmai Injection, a national medical insurance category A product, is recommended for severe cases of COVID-19 in clinical treatment guidelines[40]. - The company has established long-term partnerships with numerous top-tier hospitals and universities, enhancing its R&D capabilities[47]. Financial Management and Strategy - The company plans not to distribute cash dividends or issue bonus shares[7]. - The company emphasizes brand building as a systematic project, continuously investing to enhance brand market awareness and influence[43]. - The company has established a diverse sales channel strategy, including academic promotion and OTC market expansion, to enhance sales performance[42]. - The company has implemented strict internal control systems to protect the rights of shareholders and creditors, ensuring timely disclosure of major information[77]. - The company aims to enhance shareholder value through strategic investments and operational improvements[149]. Risks and Compliance - The company faces risks related to industry policy adjustments, rising production costs, R&D challenges, inventory price declines, talent shortages, and environmental regulations[65][66]. - The company plans to actively monitor and respond to potential risks to achieve its operational goals for 2023[66]. - The company has not received any administrative penalties for environmental issues during the reporting period[74]. - The company has established a comprehensive emergency response mechanism for environmental pollution incidents, including a specific emergency plan and regular employee training[75]. Shareholder Information - The total number of shares remained unchanged at 330,951,600 during the reporting period[106]. - The major shareholder Zhang Yisheng holds 39.08% of the shares, totaling 129,348,530 shares[111]. - The total number of ordinary shareholders at the end of the reporting period was 26,051[110]. - The company aims to protect the interests of minority investors while resolving the shareholding representation issue[114]. Accounting and Financial Reporting - The financial report for the first half of 2023 has not been audited[123]. - The financial statements are prepared in RMB, with the balance sheet dated June 30, 2023[124]. - The company adheres to the accounting standards set by the Ministry of Finance, ensuring the financial statements are true and complete[162]. - The company recognizes deferred tax assets related to deductible temporary differences if new information indicates that the economic benefits can be realized within 12 months post-acquisition, reducing goodwill accordingly[168]. Inventory and Assets - The company recognizes inventory when it is likely that economic benefits will flow to the enterprise and the cost can be reliably measured[195]. - Inventory is measured at the lower of cost and net realizable value, with provisions for inventory write-downs recorded when costs exceed net realizable value[196]. - The company uses a perpetual inventory system for tracking inventory[197]. - The company conducts physical inventory counts of consumable biological assets between July and October each year[199].